Search
for
Sort by
Research 30 of 1000+
- B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- B‐ RAF , naevi and melanoma: a complex relationship
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Network pharmacology and molecular docking analysis on potential molecular targets and mechanism of action of BRAF inhibitors for application in wound healing
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors
- Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF V 600R mutation
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Melanocytes: The new Black
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Cutaneous toxicities of new treatments for melanoma
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- RASopathic alopecia: Hair changes associated with vemurafenib therapy
- Management of Dermatologic Toxicities
- Vemurafenib-induced pityriasis amiantacea: a case report
- Hair(y) Matters in Melanoma Biology
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Diagnosis and Management of Melanoma of the Scalp: A Review of the Literature
- At the Root: Cutaneous Langerhans Cell Histiocytosis